Eli Lilly Aims To Expand Weight-Loss Drug Trials To Those At Risk, Not Just Overweight
Eli Lilly Aims To Expand Weight-Loss Drug Trials To Those At Risk, Not Just Overweight
Ricks also mentioned the potential for expanding the use of these drugs to individuals with a BMI below 25 who are classified as having a healthy weight but are at risk of conditions like diabetes or vascular dementia. He emphasized the need to consider different BMI cut-offs for certain ethnic groups, such as Pacific Islanders, who are known to contract type-two diabetes earlier and at a lower BMI.In a groundbreaking move, Eli Lilly (NYSE:LLY) is set to test its weight-loss medications on individuals who are not overweight but are at risk of gaining weight.
以开创性举措，伊莱利·(纽交所:LLY)将对非超重但有增重风险的个体进行减重药物测试。
What Happened: Dave Ricks, CEO of Eli Lilly, announced that the company is considering lowering the BMI threshold for its anti-obesity drugs, Mounjaro and Zepbound. Currently, the BMI cut-off for trials is 27 in the U.S. and northern Europe. Ricks suggested that a BMI of 25 might be more suitable, Financial Times reported on Monday.
发生的事情：伊莱利公司的首席执行官戴夫·瑞克斯宣布，该公司正在考虑将其抗肥胖药物Mounjaro和Zepbound的BMI阈值降低。目前，美国和北欧的试验BMI截止线为27。瑞克斯建议BMI为25可能更合适，据《金融时报》周一报道。
Ricks pointed out that trials for Zepbound and the experimental weight-loss pill orforglipron included patients with a BMI of 30 and above, or those with a BMI of 27 and above with weight-related health issues. He argued for lowering the threshold, especially for orforglipron, which results in more modest weight loss.
瑞克斯指出，Zepbound和实验性减重药物orforglipron的试验包括BMI为30及以上的患者，或BMI为27及以上且存在与体重有关的健康问题的患者。他主张降低阈值，特别是针对orforglipron，这将导致更为适中的减重。
Ricks also mentioned the potential for expanding the use of these drugs to individuals with a BMI below 25 who are classified as having a healthy weight but are at risk of conditions like diabetes or vascular dementia. He emphasized the need to consider different BMI cut-offs for certain ethnic groups, such as Pacific Islanders, who are known to contract type-two diabetes earlier and at a lower BMI.
瑞克斯还提到了扩大这些药物使用范围的潜力，即针对BMI低于25但被归类为健康体重但有患糖尿病或血管性痴呆等疾病风险的个体。他强调需要考虑某些种族群体的不同BMI截止线，比如太平洋岛民已知肥胖型糖尿病较早发病且BMI较低。
The demand for Zepbound and Novo Nordisk's Wegovy has led to shortages, prompting both companies to invest heavily in manufacturing capacity. Eli Lilly has discouraged the off-label use of Zepbound for cosmetic purposes, emphasizing the need to prioritize diabetic and obese patients.
对Zepbound和诺洛诺的薇冠(受欢迎的减重药)的需求导致了短缺，促使两家公司大力投资制造业-半导体。伊莱利公司反对将Zepbound以化妆品为目的非规定使用，强调需要优先考虑糖尿病患者和肥胖患者。
Why It Matters: The decision to lower the BMI threshold for weight-loss drug trials comes at a time when Eli Lilly is experiencing significant success in the weight-loss drug market. The company's stock has soared due to the success of its weight-loss medications. However, the company is also facing competition from knockoff drugs, which it claims could be unsafe.
为什么重要：在伊莱利在减重药市场取得巨大成功的同时，降低减重药试验的BMI阈值是一个重要决定。由于其减重药物的成功，公司股票飙升。然而，公司也面临着仿冒药物的竞争，公司声称这些药物可能不安全。
Additionally, Eli Lilly stock hit resistance after a significant rally. This indicates that while the company is performing well, it is also navigating market challenges and competition.
此外，伊莱利股票在一个重大涨幅后遇到了支撑位。这表明尽管公司表现良好，但也在应对市场挑战和竞争。
- Has Medical Marijuana Been Forgotten In Cannabis Reform? 'Its Therapeutic Benefits Are Critical'
- 医疗大麻在大麻改革中被遗忘了吗？'其疗效至关重要'
Photo via Shutterstock
图片来自shutterstock。
This story was generated using Benzinga Neuro and edited by Pooja Rajkumari
本报道使用Benzinga Neuro生成，并由Pooja Rajkumari编辑
